Diabetic RetinopathySymptoms, Doctors, Treatments, Advances & More
Learn About Diabetic Retinopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Joslin Diabetes Center
Jennifer Sun is an Ophthalmologist practicing medicine in Boston, Massachusetts. Dr. Sun is rated as an Elite provider by MediFind in the treatment of Diabetic Retinopathy. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Diabetic Retinopathy, Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal. Dr. Sun is board certified in American Board Of Ophthalmology.
Joslin Diabetes Center
Lloyd Aiello is an Ophthalmologist practicing medicine in Boston, Massachusetts. Dr. Aiello is rated as an Elite provider by MediFind in the treatment of Diabetic Retinopathy. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Diabetic Retinopathy, Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal. Dr. Aiello is board certified in American Board Of Ophthalmology.
Cleveland Clinic Main Campus
Peter Kaiser is an Ophthalmologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 38 years. Dr. Kaiser is rated as an Elite provider by MediFind in the treatment of Diabetic Retinopathy. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Vitrectomy, and Osteotomy. Dr. Kaiser is board certified in American Board Of Ophthalmology, 1998.
Summary: The objective of this study is to investigate the efficacy of implementing the AI-SaMD(VUNO Med®-Fundus AI™) alongside routine clinical practice for the detection of diabetic retinopathy.
Summary: The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are: Which OCT and OCT angiography biomar...